拜瑞妥治疗效果好吗？

Xarelto is an oxazolidinone-derived selective FXa inhibitor that acts on the active site of factor Xa (FXa). It inhibits thrombosis by inhibiting FXa and inhibiting the intrinsic and extrinsic coagulation pathways in a dose-dependent manner. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Xarelto does not inhibit thrombin and has no proven effect on platelets. A dose-dependent inhibition of factor xa activity by Xarelto has been observed in humans. Today we will learn about the effectiveness of Xarelto treatment?

Xarelto indications are: 1. Used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

In terms of treatment effect, an international scientific research team published a paper in The Lancet magazine stating that through analysis of data from a multi-center, randomized, double-blind clinical trial called "BECORD4", among a total of more than 3,000 patients, researchers confirmed that compared with standard therapy using enoxaparin, patients treated with Xarelto reduced the risk of venous thromboembolism after orthopedic surgery by about one-third.

"This is the first oral anticoagulant drug with better efficacy than the current standard therapy. Therefore, it may become a new clinical treatment option for preventing severe blood clots after major orthopedic surgery," said Professor A. Turpai from McMaster University in Canada. "At the same time, Xarelto, a new drug, also has better economics."

The effect of Xarelto on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants.

The above is the content of Xarelto effect, I hope it can help you!